Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression.
This clinical study is designed to test the hypothesis that Lurasidone in combination with
either Lithium or Divalproex is effective among patients with bipolar I depression.